Recent Articles
Weekly Psychedelic Policy Briefing: October 5, 2026
A DEA judge has paused the hearing on moving all marijuana to Schedule III while he decides whether to admit a GAO report on gaps in federal scheduling procedures. Also this week: New Mexico advocates push back on the medical psilocybin program’s certifying-clinician rule, Oregon’s psilocybin program faces a $3.8 million shortfall, and ARPA-H launches SURPASS.
By Jack Gorsline
Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.
By Joe Moore
Filter
When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference
Most psychedelic experiences pass without incident, but when one turns into a crisis, the people…
By By Sara Gael, MA, LPC
Weekly Psychedelic Policy Briefing: September 30th, 2026
DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum…
By Jack Gorsline
Weekly Psychedelic Policy Briefing, September 21, 2026
The FDA heard 80 speakers on the future of psychedelic drugs, and its federal panel…
By Jack Gorsline
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Optimi Health has Health Canada authorization for a Phase 2 trial of natural psilocybin in…
By Jack Gorsline
What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics
Reuters attributed a quote about access and reimbursement to Lynn Watkins at Monday’s FDA hearing…
By Joe Moore
Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans
Veterans built the psychedelic policy movement in state legislatures. This year, firefighters, police officers, and…